Journal Watch · Frontiers in Immunology · 2026

IgA anti-CD74 autoantibodies are associated with treatment escalation in peripheral psoriatic arthritis.

Their independent association with treatment escalation in pPsA supports further evaluation as a biomarker candidate, although findings remain exploratory and require validation in larger longitudinal cohorts.

Elsaghir A, Kuske L, Kniesch K et al.Frontiers in Immunology4 min readPharma relevance 65/100

DOI: 10.3389/fimmu.2026.1821206PMID: 42282961Study type: cohort / observational clinical study

TL;DR

Their independent association with treatment escalation in pPsA supports further evaluation as a biomarker candidate, although findings remain exploratory and require validation in larger longitudinal cohorts.

Key findings

  • In multivariate analyses, anti-CD74 was independently associated with csDMARD (OR 1.113, p = 0.022) and bDMARD use (OR 1.052, p = 0.02).
  • After false discovery rate (FDR) correction, anti-CD74 remained associated with serum IgA (q = 0.0008) and weakly with IgG (q = 0.0250), but not with C-reactive protein (CRP) or age.
  • Longitudinal associations were not significant after FDR correction (csDMARD initiation: p = 0.047, q = 0.094; bDMARD initiation: p = 0.19, q = 0.1866), indicating these findings are exploratory.<h4>Conclusion</h4>IgA anti-CD74 levels are elevated in PsA and appear to reflect immunological activity not captured by CRP.
  • Their independent association with treatment escalation in pPsA supports further evaluation as a biomarker candidate, although findings remain exploratory and require validation in larger longitudinal cohorts.

Numbers at a glance (from the abstract)

31.5%43.2%2.3%OR 1.113OR 1.052p < 0.0001p = 0.04p = 0.022p = 0.02p = 0.047p = 0.19

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

A prospective subgroup of 53 early pPsA patients was followed to assess treatment initiation.<h4>Results</h4>IgA anti-CD74 levels were elevated in PsA compared with NRD controls (median 13 vs. 6 U/mL, p < 0.0001), with similar levels in pPsA and axPsA and comparable values in RA, indicating an association with inflammatory disease rather than disease specificity. Anti-CD74 positivity (>15 U/mL) was observed in 31.5% of pPsA and 43.2% of axPsA versus 2.3% of NRD, independent of disease duration. Anti-CD74 levels were associated with treatment escalation in pPsA, with higher levels in bDMARD-treated patients (median 13.0 vs. 11.0 U/mL, p = 0.04).

Full abstract (original)

Background: <h4>Background</h4>Psoriatic arthritis (PsA) often requires escalation from conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) to biologic therapy (bDMARDs), yet biomarkers guiding treatment decisions remain limited. Anti-CD74 autoantibodies have shown diagnostic potential in axial spondyloarthritis, but their relevance in PsA is insufficiently characterized.<h4>Objective</h4>To evaluate whether IgA anti-CD74 levels are associated with treatment escalation in peripheral PsA (pPsA) and to characterize their relationships with clinical and immunological parameters.<h4>Methods</h4>Serum samples from 171 PsA (127 pPsA, 44 axial PsA [axPsA]), 43 non-rheumatic disease controls (NRD), and 43 rheumatoid arthritis (RA) patients were analyzed. IgA anti-CD74 levels were measured by enzyme-linked immunosorbent assay (ELISA). Patients were stratified by disease duration and treatment exposure. Correlation analyses, receiver operating characteristic (ROC) curves, and logistic regression models were performed.

What they did: A prospective subgroup of 53 early pPsA patients was followed to assess treatment initiation.<h4>Results</h4>IgA anti-CD74 levels were elevated in PsA compared with NRD controls (median 13 vs. 6 U/mL, p < 0.0001), with similar levels in pPsA and axPsA and comparable values in RA, indicating an association with inflammatory disease rather than disease specificity. Anti-CD74 positivity (>15 U/mL) was observed in 31.5% of pPsA and 43.2% of axPsA versus 2.3% of NRD, independent of disease duration. Anti-CD74 levels were associated with treatment escalation in pPsA, with higher levels in bDMARD-treated patients (median 13.0 vs. 11.0 U/mL, p = 0.04).

Results & conclusions: In multivariate analyses, anti-CD74 was independently associated with csDMARD (OR 1.113, p = 0.022) and bDMARD use (OR 1.052, p = 0.02). After false discovery rate (FDR) correction, anti-CD74 remained associated with serum IgA (q = 0.0008) and weakly with IgG (q = 0.0250), but not with C-reactive protein (CRP) or age. Longitudinal associations were not significant after FDR correction (csDMARD initiation: p = 0.047, q = 0.094; bDMARD initiation: p = 0.19, q = 0.1866), indicating these findings are exploratory.<h4>Conclusion</h4>IgA anti-CD74 levels are elevated in PsA and appear to reflect immunological activity not captured by CRP. Their independent association with treatment escalation in pPsA supports further evaluation as a biomarker candidate, although findings remain exploratory and require validation in larger longitudinal cohorts.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1821206 · PubMed 42282961.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Frontiers in Immunology study find?

Their independent association with treatment escalation in pPsA supports further evaluation as a biomarker candidate, although findings remain exploratory and require validation in larger longitudinal cohorts.

What type of study is this?

It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. A prospective subgroup of 53 early pPsA patients was followed to assess treatment initiation.<h4>Results</h4>IgA anti-CD74 levels were elevated in PsA compared with NRD controls (median 13 vs.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1821206. PubMed ID: 42282961. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Elsaghir A, Kuske L, Kniesch K et al.. IgA anti-CD74 autoantibodies are associated with treatment escalation in peripheral psoriatic arthritis.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1821206.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/iga-anti-cd74-autoantibodies-are-associated-with-treatment-escalation-in-821206/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides